...which Gilead Sciences Inc. (NASDAQ:GILD) bought for $11.2 billion in 2012, gaining HCV blockbuster Sovaldi sofosbuvir...

...which Gilead Sciences Inc. (NASDAQ:GILD) bought for $11.2 billion in 2012, gaining HCV blockbuster Sovaldi sofosbuvir.Institutional...

...which Gilead Sciences Inc. (NASDAQ:GILD) bought for $11.2 billion in 2012, gaining HCV blockbuster Sovaldi sofosbuvir.For...

...Inc., which Gilead took out for $11.2 billion in 2012, gaining HCV blockbuster therapy Sovaldi sofosbuvir...

...controversies clouded the roll-out in 2013 of the first highly effective Hepatitis C treatment. Sovaldi sofosbuvir...
...More than three million people in the U.S. are living with HCV, and prior to Sovaldi’s...
...The benefits are becoming apparent outside the U.S. In Egypt, where Gilead’s agreement to license sofosbuvir...

...with chemotherapy. Other notable additions to the NRDL include HCV drugs Epclusa sofosbuvir/velpatasvir and Harvoni sofosbuvir/ledipasvir...

...2011 for $11 billion, obtaining Sovaldi sofosbuvir when that compound was in Phase III testing. Sovaldi...

...glecaprevir/pibrentasvir from AbbVie Inc. (NYSE:ABBV), Zepatier grazoprevir/elbasvir from Merck & Co. Inc. (NYSE:MRK) and Vosevi sofosbuvir/velpatasvir/voxilaprevir...

...leadership, Gilead developed the HCV combination regimens that were built off the backbone of Sovaldi sofosbuvir...

...Gilead Sciences Inc. (NASDAQ:GILD) subsidiary Asegua Therapeutics LLC to provide an authorized generic of Epclusa sofosbuvir/velpatasvir...
...based on smaller data sets than normally required. Jonathan Block, Associate Editor Epclusa (Brand), sofosbuvir/GS-5816 (Compound #), sofosbuvir/velpatasvir...